Delmitide acetate_product_DataBase

Bioactivity

Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide acetate inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide acetate can be used for the research of ulcerative colitis[1][2].

In Vivo

Delmitide acetate (oral; 2.5, 5, 10 mg/kg; daily) significantly reduced CPT-11induced diarrhea, mucosal inflammation, and mortality in mice by suppressing the overproduction of proinflammatory cytokines TNF-a, IFN-y, and IL-12 in vivo[2]. Delmitide acetate (oral; 2.5, 5, 10 mg/kg; daily) generates an enhanced tumor response and prolongation of time to relapse without concomitant Gl toxicity in mice[2].

Name

Delmitide acetate

CAS

501019-16-5

Sequence

d(Arg-{Nle}-{Nle}-{Nle}-Arg-{Nle}-{Nle}-{Nle}-Gly-Tyr-NH2)

Shortening

d(R-{Nle}-{Nle}-{Nle}-R-{Nle}-{Nle}-{Nle}-GY-NH2)

Formula

C59H105N17O11.C2H4O2

Molar Mass

1288.62

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Reference

[1]. Arthur Kaser, et al. Novel therapeutic targets in the treatment of IBD. Kaser, Arthur; Tilg, Herbert (2008). Expert Opinion on Therapeutic Targets, 12(5), 553–563. [2]. Jingsong Zhao, et al. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res. 2004 Apr 15;10(8):2851-9.

PeptideDB

Delmitide acetate

CAS: 501019-16-5 F: C59H105N17O11.C2H4O2 W: 1288.62